Kazakhstan plans to produce COVID-19 vaccine at pharmaceutical plant in Zhambyl region

Kazakhstan plans to produce COVID-19 vaccine at pharmaceutical plant in Zhambyl region
The Research Institute for Biological Safety Problems of Zhambyl region is ready to conduct clinical trials of a domestic vaccine against the novel coronavirus that was named ‘KAZ COVID-In’. The inactivated vaccine was registered with the World Health Organization. The vaccine is considered the main candidate for mass immunization of the population among five domestic drugs.
 
“The vaccine is a chemically killed and purified coronavirus, which is mixed with an adjuvant. It is a known technology, based on which we first decided to make the same vaccine. We use the same technology with other viruses. Besides, scientists of our institute are well acquainted with this technology and it takes less time to manufacture it,” said Head of the Laboratory for Especially Dangerous Infectious Diseases Lespek Kutumbetov.
 
Scientists say that the human trials of the COVID-19 vaccine will start in September. 44 volunteers are expected to take part in the first phase, while the second phase will cover 200 people. Under normal conditions, the third and fourth phases have to be also completed in order for the vaccine to be accepted for mass use.
 
The domestic vaccine will be produced at the plant under construction in Kordai district of Zhambyl region. Governor of Zhambyl region Berdibek Saparbayev reviewed the progress of the construction. He stressed the importance of the timely commissioning of the facility.
 
“The plant should be put into operation this year. This is especially important amidst the pandemic. It is planned to produce there immunobiological drugs, including a vaccine against coronavirus infection,” Saparbayev said.
 
The biopharmaceutical plant will produce immunobiological drugs in line with the international standard of good manufacturing practice (GMP), including the COVID-19 vaccine. The plant will also produce vaccines against pandemic influenza, tuberculosis, brucellosis, nodular prurigo and infectious animal diseases.  Up to 60 million doses of biopharmaceuticals per year are planned to be produced there.
 
 
Photo: 24.kz